Open Research Newcastle
Browse

Why maximum tolerated dose?

Download (3.55 MB)
journal contribution
posted on 2025-05-08, 23:22 authored by Hans G. Stampfer, Genevieve M. Gabb, Simon DimmittSimon Dimmitt
A long‐established approach to the pharmacological treatment of disease has been to start low and go slow. However, clinicians often prescribe up to maximum tolerated dose (MTD), especially when treating acute and more severe disease, without evidence to show that MTD is more likely to improve outcomes. Cardiovascular guidelines for some indications advocate MTD even in prevention, for example hypercholesterolaemia, without compelling evidence of better outcomes. This review explores the origins and potential problems of prescribing medications at MTD. Oral effective dose 50 (ED50) may be a useful guide for balancing efficacy and safety.

History

Journal title

British Journal of Clinical Pharmacology

Volume

85

Issue

10

Pagination

2213-2217

Publisher

Wiley-Blackwell

Language

  • en, English

College/Research Centre

Faculty of Health and Medicine

School

School of Medicine and Public Health

Rights statement

This is the peer reviewed version of above article, which has been published in final form at https://doi.org/10.1111/bcp.14032. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Usage metrics

    Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC